At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 23 enrolled
Drug / intervention
FP +2 moredrug
Likely dose
FP 100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week, Randomised, Double-blind, Placebo-controlled, Three-period, Cross-over Pilot Study Comparing the Effect of Salmeterol/Fluticasone Propionate, Fluticasone Propionate and Placebo on Perpheral Blood Eosinophils and Serum IL-5 in Response to Allergen Challenge in Asthma Subjects When Allergen Challenge is Administered at 1 Hour or 11-12 Hours Post-dose of the Dosing Interval
In Brief
A Phase 4 clinical trial evaluating FP, SFC, and 1 other intervention for Asthma. Completed, enrolled 23 participants across 2 sites in 2 countries.
Detailed Summary
The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is influenced by the time of allergen challenge relative to the time of dosing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedAug 17, 2007
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.9 years ago
Interventions
FPdrug
Fluticasone Propionate 100 mcg BD
SFCdrug
Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
Placebodrug
Matching Placebo